Literature DB >> 8099271

HIV infection in haemophilia--a European cohort.

A Aronstam1, B Congard, D I Evans, C F Gazengel, U Herberg, F G Hill, P M Jones, R Ljung, E P Mauser-Bunschoten, E Scheibel.   

Abstract

Ten haemophilia centres in northern Europe have pooled data on 202 haemophilic children who were infected with HIV between 1979 and 1986. All cases were under 16 years of age on 1 July 1985. The age at infection ranged from 1-15 years. Thirty seven cases (18%) had progressed to AIDS by 1 July 1991 and 15 of these have died. Persistent generalised lymphadenopathy has been noted in 102 patients of whom 18 (17%) have developed AIDS. Twenty three of the remaining patients (23%) have not. CD4+ T cell counts have fallen steadily. Of 36 patients who have had shingles since seroconversion, 19 (53%) had counts below 0.2 x 10(9)/l. Thirty five out of 145 patients without shingles (24%) had similar values. The mean IgA concentration in patients with CD4+ T cell counts above 0.5 x 10(9)/l was 2.38 g/l, between 0.2 and 0.5 was 3.07 g/l, and in those with CD4+ T cell counts below 0.2 x 10(9)/l the mean IgA concentration was 4.58 g/l. Treatment patterns have altered between 1989 and 1991, with increased use of zidovudine in patients without AIDS and a marked increase in primary prophylaxis against pneumocystis pneumonia. This has been associated with a decline in the incidence of pneumocystis as an indicator disease in new AIDS cases from 56% in 1989 to 20% in 1991. These observations indicate that persistent generalised lymphadenopathy does not worsen the outlook, but shingles does. Rising IgA concentrations are markers for disease progression. Modern prophylactic regimens are delaying the onset of indicator disease, but CD4 values continue to fall steadily.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099271      PMCID: PMC1029282          DOI: 10.1136/adc.68.4.521

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

Review 1.  Factor concentrates for treatment of hemophilia: which one to choose?

Authors:  D B Brettler; P H Levine
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

2.  The natural history of human immunodeficiency virus infection in a haemophilic cohort.

Authors:  C A Lee; A Phillips; J Elford; E J Miller; M Bofill; P D Griffiths; P B Kernoff
Journal:  Br J Haematol       Date:  1989-10       Impact factor: 6.998

3.  A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia.

Authors:  J J Goedert; C M Kessler; L M Aledort; R J Biggar; W A Andes; G C White; J E Drummond; K Vaidya; D L Mann; M E Eyster
Journal:  N Engl J Med       Date:  1989-10-26       Impact factor: 91.245

4.  Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses.

Authors:  J L Sullivan; F E Brewster; D B Brettler; A D Forsberg; S H Cheeseman; K S Byron; S M Baker; D L Willitts; R A Lew; P H Levine
Journal:  J Pediatr       Date:  1986-04       Impact factor: 4.406

5.  Human immunodeficiency virus infection in hemophilic children.

Authors:  J M Jason; J Stehr-Green; R C Holman; B L Evatt
Journal:  Pediatrics       Date:  1988-10       Impact factor: 7.124

6.  Progression of HIV disease in a haemophilic cohort followed for 11 years and the effect of treatment.

Authors:  C A Lee; A N Phillips; J Elford; G Janossy; P Griffiths; P Kernoff
Journal:  BMJ       Date:  1991-11-02

7.  HIV-1 infection in a cohort of haemophilic patients.

Authors:  N Wagner; R Bialek; H Radinger; M Becker; K E Schneweis; H H Brackmann; D Niese
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

8.  Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.

Authors:  L M Aledort; M W Hilgartner; M C Pike; G F Gjerset; M A Koerper; E Y Lian; J M Lusher; J W Mosley
Journal:  BMJ       Date:  1992-01-25

9.  Intravenous immunoglobulin in HIV-I infected haemophilic patients.

Authors:  N Wagner; R Bialek; H Radinger; H H Brackmann; M Becker
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

10.  Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort.

Authors:  R J Cuthbert; C A Ludlam; J Tucker; C M Steel; D Beatson; S Rebus; J F Peutherer
Journal:  BMJ       Date:  1990-10-27
  10 in total
  3 in total

1.  Gene therapy for haemophilia.

Authors:  Akshay Sharma; Manu Easow Mathew; Vasumathi Sriganesh; Ulrike M Reiss
Journal:  Cochrane Database Syst Rev       Date:  2020-04-28

Review 2.  Current options and new developments in the treatment of haemophilia.

Authors:  Trisha Wong; Michael Recht
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 3.  Gene therapy for haemophilia.

Authors:  Akshay Sharma; Manu Easow Mathew; Vasumathi Sriganesh; Ulrike M Reiss
Journal:  Cochrane Database Syst Rev       Date:  2016-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.